CRISPR In Brief
Executive Summary
CRISPR/Cas9 gene editing is fast, efficient and specific. How does it work?
You may also be interested in...
CRISPR/Cas9 Patent Battle: What's Happened, What's Next?
With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.
Can CRISPR Make The Jump To Therapeutics?
Biomedical researchers are rapidly adopting the new gene-editing technology CRISPR/Cas9 for lab experiments, but can CRISPR also become the basis for new treatments of human disease? At least two venture-backed start-ups can't wait to find out.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.